Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?
Authors:
- 10 February 2006
- journal article
- review article
- Published by Wiley in Internal Medicine Journal
- Vol. 36 (2) , 72-76
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?Arthritis & Rheumatism, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitisArthritis & Rheumatism, 2005
- Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005
- Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Biological therapies in the spondyloarthritides--the current stateRheumatology, 2004
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trialArthritis & Rheumatism, 2003
- Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitisArthritis & Rheumatism, 2003
- Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor αNew England Journal of Medicine, 2002
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002